Kelly K. Hunt – författare

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Kelly Hunt, is devoted to Breast Cancer. Dr. Hunt has assembled expert authors to review the following topics: Tomosynthesis in breast cancer imaging: how does it fit into preoperative evaluation and surveillance?; Lobular breast cancer: different disease, different algorithms?; Hypofractionated radiation therapy in breast conserving therapy; Oncoplastic breast reconstruction: should all patients be considered?; Neoadjuvant endocrine therapy: who benefits most?; Breast cancer disparities: how can we leverage genomics to improve outcomes?; Anatomy and breast cancer staging: is it still relevant?; When does atypical ductal hyperplasia require surgical intervention?; Surgical intervention for lymphedema; Are there alternative strategies in the local management of DCIS?; Genetic testing and genetic counseling: what is standard of care?; Molecular subtypes and local-regional control of breast cancer; Intraoperative margin assessment in breast cancer management; Triple negative breast cancer: who should receive neoadjuvant chemotherapy?; and more!

This second edition of Breast Cancer continues the tradition of the M. Multidisciplinary care is a popular term today, but such care has been practiced at M. The chapters start, logically, with prevention of breast cancer and p- sonalized risk assessment, including genetics.

Selected as a Doody’s Essential Title for 2025​!Presented by the American College of Surgeons and the Alliance for Clinical Trials in Oncology, the first comprehensive, evidence-based examination of cancer surgery techniques as standards distills the well-defined protocols and techniques that are critical to achieve optimal outcomes in a cancer operation. This unique, one of a kind collaboration between the American College of Surgeons and the Alliance for Clinical Trials in Oncology focuses on best practices and state-of-the-art methodologies. Operative Standards for Cancer Surgery clearly describes the surgical activities that occur between skin incision and skin closure that directly affect cancer outcomes.Key FeaturesQuickly grasp the proper technical elements of a cancer operation through clear, practical text and more than 120 illustrations. Benefit from careful analysis of the best evidence available in the literature, gathered here to create the highest quality standards in four key disease sites: breast, colon, lung, and pancreas. Learn from experts drawn from diverse groups including the American College of Surgeons, the Alliance for Clinical Trials in Oncology, the National Cancer Institute Cooperative Groups, and the Commission on Cancer, as well as national societies and organizations with an interest in these four cancer types. Now with the print edition, enjoy the bundled interactive eBook edition, offering tablet, smartphone, or online access to: Complete content with enhanced navigation . Powerful search tools and smart navigation cross-links that pull results from content in the book, your notes, and even the web. Cross-linked pages, references, and more for easy navigation. Highlighting tool for easier reference of key content throughout the text. Ability to take and share notes with friends and colleagues. Quick reference tabbing to save your favorite content for future use.

The possibility of treating cancer, a disease defined by genetic defects, by introducing genes targeting these very alterations has led to an immense interest in gene therapy for cancer. Although incremental successes have been realized, enthusiasm for gene therapy has declined due to an increasing number of obstacles. These obstacles include vector systems that do not reach systemic metastases, therapeutic genes with redundant mec- nisms allowing for cellular resistance, and toxicities in clinical trials leading to premature closure of these studies. Different tactics to overcome or circumvent these obstacles have catalyzed the development of a wide range of gene therapy approaches. Thus far, almost two-thirds of gene therapy trials have focused on cancer. This reflects the concept that gene therapy approaches for the treatment of cancer do not necessarily require long-term expression of the gene as is necessary for the treatment of primary genetic defects like hemophilia or juvenile diabetes. Unlike the treatment of genetic defects, where expr- sion of the corrected gene needs to be strong, permanent and, sometimes regulated, tactics to treat tumors can be based on temporary and locally limited effects. In addition, cancer cells have different properties than normal cells and this allows for targeting gene therapy to specific cells, a major advantage over current antitumor therapies, which are also toxic to normal cells and tissues.